Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

Armin Ghobadi, MD, Michael P. Rettig, PhD, Amanda F Cashen, MD, Leah Gehrs, Stephanie Christ, MS, Neha Mehta-Shah, MD, Peter Westervelt, MD PhD, Brad S. Kahl, MD, Nancy L. Bartlett, MD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142464

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

Armin Ghobadi, MD, Kahee A Mohammed, MDMPH, Rawan Faramand, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Nicholas J. Short, MD, Feng Gao, MD PhD MPH, Geoffrey L Uy, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Richard E. Champlin, MD, Farhad Ravandi, MBBS, Partow Kebriaei, MD

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-141143

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136828

Published: 2020

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Francesca Ferraro, MD PhD, Christopher A Miller, PhD, Amy Abdalla, Nichole Helton, Nathan Salomonis, PhD, Robert S Fulton, Catrina Fronick, BS, Sharon E Heath, Peter Westervelt, MD PhD, Timothy J Ley, MD

Blood (2019) 134 (Supplement_1): 3827.

https://doi.org/10.1182/blood-2019-122967

Published: 2019

Journal Articles

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Luke Eastburg, MD, David A. Russler-Germain, MDPhDBS, Ramzi Abboud, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD, Michael W. Becker, MD, Neha Kumar, MD, Omar S. Aljitawi, MD, Jeffrey R. Andolina, MD MS, Thomas J Fountaine, MD, Jane L. Liesveld, MD, Eric Huselton, MD

Blood (2019) 134 (Supplement_1): 4496.

https://doi.org/10.1182/blood-2019-129872

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Blood (2018) 132 (Supplement 1): 5277.

https://doi.org/10.1182/blood-2018-99-114979

Published: 2018

Journal Articles

Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone

Francesca Ferraro, MD PhD, Christopher A Miller, PhD, Nichole Helton, Robert S Fulton, Catrina Fronick, BS, Sharon E Heath, Peter Westervelt, MD PhD, Timothy J Ley, MD

Blood (2018) 132 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2018-99-117288

Published: 2018

Journal Articles

Prognostic Significance of Minimal Residual Disease in Patients with Secondary Acute Myeloid Leukemia

Chi-Joan How, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Feng Gao, PhD, Rizwan Romee, MD

Blood (2017) 130 (Supplement 1): 5085.

https://doi.org/10.1182/blood.V130.Suppl_1.5085.5085

Published: 2017

Journal Articles

Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS

Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Geoffrey L. Uy, MD, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2016) 128 (22): 4658.

https://doi.org/10.1182/blood.V128.22.4658.4658

Published: 2016

Journal Articles

The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation

Michael Slade, BA, Scott R Goldsmith, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Todd A Fehniger, MD PhD, Mark A. Schroeder, MD, Rizwan Romee, MD

Blood (2016) 128 (22): 4697.

https://doi.org/10.1182/blood.V128.22.4697.4697

Published: 2016

Journal Articles

Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation

Jason Thomas Romancik, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Kathryn Trinkaus, PhD, Rizwan Romee, MD

Blood (2016) 128 (22): 4698.

https://doi.org/10.1182/blood.V128.22.4698.4698

Published: 2016

Journal Articles

ABO Mismatch Status Does Not Influence the Clinical Outcomes in Haploidentical Hematopoeitic Cell Transplantation

Bita Fakhri, MD MPH, Michael Slade, BA, Cory Jensen, BS, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Rizwan Romee, MD

Blood (2016) 128 (22): 4699.

https://doi.org/10.1182/blood.V128.22.4699.4699

Published: 2016

Journal Articles

Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Matt Christopher, MD PhD, Allegra A. Petti, PhD, Christopher Miller, PhD, Lukas D. Wartman, MD, Jacqueline E. Payton, MD PhD, Sharon Heath, Robert Fulton, John S. Welch, MD PhD, Matthew J. Walter, MD, Peter Westervelt, MD PhD, Daniel C. Link, MD, Richard K Wilson, PhD, Timothy J. Ley, MD, John F. DiPersio, MD, PhD

Blood (2016) 128 (22): 1528.

https://doi.org/10.1182/blood.V128.22.1528.1528

Published: 2016

Journal Articles

DNMT3A -Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression

David Spencer, MDPhD, David Russler-Germain, Nichole M Helton, B.S., Tamara L Lamprecht, B.S., Marwan Shinawi, MD, Peter Westervelt, MD PhD, Jacqueline E. Payton, MD PhD, Robert S. Fulton, PhD, Richard K Wilson, PhD, Matthew J. Walter, MD, Daniel C. Link, MD, John F. DiPersio, MD, PhD, Timothy J. Ley, MD

Blood (2016) 128 (22): 1050.

https://doi.org/10.1182/blood.V128.22.1050.1050

Published: 2016

Journal Articles

Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy)

Steven H Borson, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Mark A. Schroeder, MD, Rizwan Romee, MD, Cory Jensen, BS

Blood (2016) 128 (22): 5883.

https://doi.org/10.1182/blood.V128.22.5883.5883

Published: 2016

Journal Articles

Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

Meagan A. Jacoby, MD PhD, Eric J. Duncavage, MD, Gue Su Chang, PhD, Christopher A. Miller, PhD, Jin Shao, Kevin Elliott, Robert S. Fulton, PhD, Catrina Fronick, Michelle O'Laughlin, Daniel C. Link, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Timothy J. Ley, MD, Timothy A. Graubert, MD, Matthew J. Walter, MD, Richard K Wilson, PhD

Blood (2016) 128 (22): 5506.

https://doi.org/10.1182/blood.V128.22.5506.5506

Published: 2016

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Dhruv Bansal, MD, Pavan Kumar Bhamidipati, MBBS, MD, Natasha Catherine Edwin, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Jingxia Liu, Rizwan Romee, MD

Blood (2016) 128 (22): 4696.

https://doi.org/10.1182/blood.V128.22.4696.4696

Published: 2016

NARROW

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

The Molecular Basis of Long First Remissions in Normal Karyotype AML Patients

Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

Evidence for Complete Mutation Clearance in Normal Karyotype AML Patients with Very Long (> 5 years) Remissions after Chemotherapy Alone

Prognostic Significance of Minimal Residual Disease in Patients with Secondary Acute Myeloid Leukemia

Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS

The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation

Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation

ABO Mismatch Status Does Not Influence the Clinical Outcomes in Haploidentical Hematopoeitic Cell Transplantation

Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

DNMT3A -Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression

Graft Lymphocyte Content Does Not Influence Outcomes after Peripheral Blood Haploidentical Transplants Using Post Transplant Cyclophosphamide (PTCy)

Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only